VERA — Vera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1831828 ·
Last close
$29.73
Market Cap
$2.14B
52W High
$56.05
52W Low
$23.05
ADV30
2,384,845
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -112,490,000 | -109,473,000 | 532,984,000 | 48,876,000 | 125,226,000 |
| Mar 2026 | 0 | — | -125,132,000 | -121,032,000 | 621,739,000 | 114,351,000 | 122,042,000 |
| Dec 2025 | 0 | — | -94,206,000 | -91,097,000 | 734,733,000 | 354,725,000 | 130,212,000 |
| Sep 2025 | 0 | — | -83,932,000 | -80,293,000 | 517,503,000 | 57,773,000 | 118,623,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-293,198,000
Investing CF
$41,153,000
Financing CF
$311,306,000
CapEx
$-616,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.96
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-881,897,000
Inventory
—
Receivables
$3,908,000
ST Investments
$482,409,000
EBIT TTM
$-361,391,000
Pretax Income TTM
$-368,952,000
Interest Exp TTM
$7,561,000
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -315,473,000 | -299,615,000 | 734,733,000 | 130,212,000 | 604,521,000 | -241,104,000 |
| Dec 2024 | 0 | -167,170,000 | -152,148,000 | 655,681,000 | 78,526,000 | 577,155,000 | -134,679,000 |
| Dec 2023 | 0 | -102,012,000 | -95,990,000 | 175,546,000 | 73,861,000 | 101,685,000 | -92,181,000 |
| Dec 2022 | 0 | -90,903,000 | -89,056,000 | 131,435,000 | 54,527,000 | 76,908,000 | -67,596,000 |
TTM Snapshot
Revenues TTM
$23,928,000
NetIncome TTM
$-368,953,000
OpCashFlow TTM
—
Assets (Latest)
$621,739,000
Forward EPS
$-4.37
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $29.73 · call volume: 85 · put volume: 101
Expected Move to 2026-10-16:
±$2.42
(8.14%) —
implied range
$27.31 –
$32.15
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc. | $2.16B | $16.22 | — |
| PHVS | Pharvaris N.V. | $2.18B | $31.12 | — |
| IMNM | Immunome Inc. | $2.19B | $19.31 | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $2.08B | $18.34 | — |
| BHC | Bausch Health Companies Inc. | $2.26B | $6.04 | — |
News headlines (Yahoo Finance, 1h cache)
Do Vera Therapeutics' (VERA) High-Profile IgAN Data Show Durable Moat or Crowded Mechanism Risk?
2026-10-08 15:15 · Yahoo
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:05 · Yahoo
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN K
2026-10-02 13:24 · Yahoo
Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints
2026-09-17 06:12 · Yahoo
Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened?
2026-09-15 20:40 · Yahoo
Vera set up for full approval for Trutakna in IgAN with Phase III win
2026-09-15 16:39 · Yahoo
Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints
2026-09-15 13:37 · Yahoo
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday
2026-09-15 13:12 · Yahoo
VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4
2026-09-15 13:08 · Yahoo
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
2026-09-15 10:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.